Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2021

		Quarter Ended Half Year Ended Year End					
Sr. No.	Particulars	30th Sept					Year Ended
		2021 Unaudited	30th June 2021 Unaudited	30th Sept 2020 Unaudited	30th Sept 2021 Unaudited	30th Sept 2020 Unaudited	31st March 2021 Audited
II	Other Income	1,896	1,092	1,428	2,986	2,991	6.60
III	Total Revenue (I + II)	1,896	1,092	1,428	2,986	2,991	6,68 6,68
IV	Expenses				2,500	2,551	0,08
	(1) Cost Materials consumed	-	_	-	20.		
	(2) Purchase of Stock-in-Trade	-	-				
	(3) Changes in Inventories of Finished Goods, Work-in- Progress and Stock-in-Trade	-	-			-	
	(4) Employee Benefits Expenses	365	352	016	510		
	(5) Depreciation and Amortisation Expenses	91	332	216	718	461	1,262
	(6) Administrative and Other Expenses	321	429	200	91		239
	(7) Finance Costs	- 021	729	200	747	631	2,07
	Total Expenses	777	781	416	1.550		-
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	1,119	311	1,012	1,556 1,430	1,092	3,572
VI	Exceptional Items	-	-			-	-,
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	1,119	311	1,012	1,430	1,899	3,108
VIII	Extra Ordinary Items					-,055	0,100
IX	Profit/(Loss) before Tax (VII-VIII)	1,119	311	1.010			-
Х	Tax Expenses	1,119	311	1,012	1,430	1,899	3,108
	(1) Current Tax						
- 10000	(2) Tax Adjustment Previous Year		-	-	-		503
	(3) Deffered Tax	-			-	56	104
XI	Profit/(Loss) for the period from continuing operations (IX - X)	1,119	311	1,012	1,430	1,843	2,501
XII	Profit/(Loss) from discontinuing operations						
XIII	Tax Expenses of discontinuing operations			-			-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-			
XV	Profit/(Loss) for the period (XI - XIV)	1110					
XVI	Other Comprehensive Income A (i) Itmes that will not be reclassified to profit or loss	1,119	311	1,012	1,430	1,843	2,501
	(ii) Income rax relating to items that will not be reclassified to profit or loss						
	B (i) Itmes that will not be reclassified to profit or loss (ii) Income rax relating to items that will not be			_			
(VII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period	1,119	311	1,012	1,430	1,843	2,501
VIII	Earnings per Share : (1) Basic (2) Diluted	0.75	0.21	0.67	0.95	1.23	1.67

Notes:

- 1 This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- 2 The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2021 have been reviewed by the Audit Committee in their Meeting held on .10.2021 and approved by the Board of Directors of its Meeting held on .10.2021. The Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- 3 The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo Pharma Laboratories Limited

Ashok Somani

Director DIN: 03063364

Date: 29th October, 2021

Place: Mumbai

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER, 2021

(Rupees in Thousand)

	(Rupees in Thous:				
Sr.	DADWIG TO THE	As at	As at		
No.	PARTICULARS	30.09.2021	31.03.2021		
		Unaudited	Audited		
.1	<u>ASSETS</u>				
1	Non-Current Assets				
	(A) Property, Plant & Equipment	490	522		
	(B) Financial Assets				
	(i) Investment	9,653	407		
	(ii) Long Term Loans	20,000	-		
	Total Non-Current Assets	30,143	929		
2	Current Assets				
	(A) Financial Assets				
	(i) Cash & Cash Equivalents	78,502	1,08,711		
	(ii) Other Current Assets	2,063	294		
	(ii) Loans	541	_		
	(B) Other Current Assets	143	95		
	Total Current Assets	81,249	1,09,100		
	TOTAL ASSETS	1,11,392	1,10,029		
2	FOURTY AND LIABILITIES				
	EQUITY AND LIABILTIES				
1	Equity	4			
	(a) Equity Share Capital	15,000	15,000		
	(b) Other Equity (Reserve & Surplus)	96,378	94,948		
	Total Equity	1,11,378	1,09,948		
2	<u>Liabilities</u>				
1	Non-Current Liabilities				
2	Current Liabilities				
	(A) Financial Liabilities		•		
	(i) Other Current Liabilities	14	81		
	(ii) Provisions	-	=		
	Total Current Liabilities	14	81		
	TOTAL EQUITY AND LIABILITIES	1,11,392	1,10,029		

By Order of the Board

For Chemo - Pharma Laboratories Limited

Date: 29th October, 2021

Place: Mumbai



Ashok Somani Director

Herelase

DIN: 03063364

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382

• CIN No.: L99999MH1942PLC003556

• PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com

• Email ID: chemopharmalab@gmail.com

STANDALONE CASH FLOW STATEMENT FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER 2021

(Rupees in Thousand)

(Mapees in Thousand				
	Half Year Ended	Year Ended		
· PARTICULARS	30.09.2021	31.03.2021		
A. CASH FLOW FROM OPERATING ACTIVITIES	Unaudited	Audited		
Net Profit before tax and extraordinary items				
Adjustement for	1,430	3,107		
Depreciation				
Dividend received	91	239		
Interest received	(50)	(4)		
Liabilities written back	(2,513)	(5,309)		
		-		
Operating profit before working capital changes Adjustement for	(1,042)	(1,967)		
▼ 14 AND OVER 1971 WAR 1972 CAN 1980 CO				
Increase (Decrease) in other Current Liabilities	(67)	(1,368)		
Decrease (increase) in Current Assets Increase in Loans Given	(2,358)	128		
Increase in Loans Given Increase in Fixed Assets	(20,000)	19,568		
	(59)	(14)		
Cash Generated From Operation Taxes Paid	(22,484)	18,314		
	-	(863)		
A. Cash Flow From Operating Activities	(23,526)	15,484		
B. CASH FLOW FROM INVESTING ACTIVITIES				
Dividend received	F0			
Interest received	50	4		
Increased / (Decrease) in Investment	2,513	5,309		
Cash Flow From Investing Activities	(9,246)	(170)		
C. CASH FLOW FROM FINANCING ACTIVITIES	(6,683)	5,143		
Interest Paid				
Cash Flow From Financing Activities		-		
- Tom I maneing Activities		-		
Net increase/(decrease) in cash and cash Equivalents	(30,209)	20,627		
Opening balance of Cash and Cash Equivalents	1,08,711	88,084		
Closing Balance Of Cash and Cash Equivalents	78,502	1,08,711		

For Chemo Pharma Laboratories Limited

Date: 29th October, 2021

Place: Mumbai

Ashok Somani Director DIN: 03063364

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office: - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L999999MH1942PLC003556 • PAN No.: AAACC2056K Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATON OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2021

Rs. in Thousand)

	STANDALONE						
PARTICULARS	UNAUDITED QUARTER ENDED			UNAUDITED HALF YEAR ENDED		AUDITED YEAR ENDED	
Reconciliation of Profit After Tax as reported earlier:	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021	
Net Profit / (Loss) for the Period (as per AS)	1,119.00	311.00	1.010.00				
Benefit / (Charge):	1,113.00	311.00	1,012.00	1,430.00	1,843.00	2,501.00	
Impact of Deferred Income (Government Grant) Amortized to Income	-				-		
Impact of Fair Valuation of Financial Instruments	-					<u> </u>	
Impact of Actuarial Gain / Loss Taken OCI	-				-		
Impact of Adjustment of Deferred Tax	-			-			
Net Profit / (Loss) for the Period (as per AS)	1,119.00	311.00	1,012.00	1,430.00	1,843.00	2,501.00	

For Chemo Pharma Laboratories Limited

Date: 29th October, 2021

Place: Mumbai

HA LASO MAY ON BOMBAY ON BOMBAY

Ashok Somani Director DIN: 03063364